

August 30, 2010

Press Release

Abbott Japan Co., Ltd.

[Notes to editors]

1. Glossary of Terms

1) Juvenile idiopathic arthritis (JIA)

JIA is an autoimmune disease that generally affects children under 16 years of age and is the most common pediatric rheumatic disease, a category of diseases that includes JIA, systemic lupus erythematosus, dermatomyositis, and polymyositis. Although the etiology of JIA is still unclear, JIA is believed to be a multifactorial disease caused by a complex combination of genetic and environmental factors. It is also

Libradoma™. In addition, Eisai is working with Sweden-based BioArctic Neuroscience Inc. to investigate potential immunotherapies for Alzheimer's disease, and is developing and marketing Humira®, a fully human anti-TNF α monoclonal antibody, in Japan in cooperation with Abbott Japan, thus demonstrating its commitment to improving the quality of life (QOL) of patients and their families by producing antibody drugs.

4. About Abbott

Headquartered in Chicago, Illinois, Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 83,000 people and markets its products in more than 130 countries.

In Japan, approximately 2,500 Abbott employees are devoted to the manufacture, development, distribution, and marketing of pharmaceuticals and medical products, including nutritionals, devices, diagnostics, and products for vision care. Abbott's main offices in Japan are located in Tokyo, Fukui, and Chiba. News releases issued by Abbott Japan and Abbott Headquarters are available at www.abbott.co.jp and www.abbott.com, respectively.

5. Abbott's Commitment to Immunology

Abbott is focused on the discovery and development of innovative treatments for immunologic diseases. The Abbott Bioresearch Center, founded in 1989 in Worcester, Mass., United States, is a world-class discovery and basic research facility committed to finding new treatments for autoimmune diseases.

More information about Humira®, including full prescribing information, is available on the Web sites <http://www.e-humira.jp> (Japanese only) and www.HUMIRA.com (English).